Johnson & Johnson JNJ has recently achieved a Golden Cross, a widely recognized bullish technical indicator that may suggest significant long-term gains. This occurs when the Stock‘s 50-day simple moving average surpasses its 200-day simple moving average, often characterizing a robust upward trend.

While this technical development generates positive sentiment, Johnson & Johnson’s latest advancements in lung cancer treatment may serve as an additional catalyst for investor interest.

Chart created using Benzinga Pro

Currently priced at $162.37, the Johnson & Johnson Stock demonstrates potential strength. However, short-term moving averages create a somewhat ambiguous outlook. The eight-day simple moving average sits at $163.37 and the 20-day at $164.45, indicating minor selling pressure. Conversely, the 50-day simple moving average at $156.24 and the 200-day moving average at $155.72 provide substantial support for a bullish trajectory.

The Moving Average Convergence Divergence (MACD) indicator currently shows a value of 1.74, reinforcing a positive outlook. Meanwhile, a Relative Strength Index (RSI) of 52.33 suggests the Stock remains in neutral territory, neither oversold nor overbought.

Read also: FDA Grants Fast Track Review To Johnson & Johnson’s Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva

In addition to technical indicators, Johnson & Johnson announced a significant advance in lung cancer treatment. The Phase 3 MARIPOSA study has shown that the combination therapy of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) notably improves survival rates for patients battling advanced non-small cell lung cancer.

The European Medicines Agency is currently considering approval for this groundbreaking treatment, which could become a major revenue source moving forward.

The recent Golden Cross indicates that Johnson & Johnson’s Stock may be on a bullish long-term trend, although short-term resistance levels could challenge the Stock’s performance.

Given the promising cancer treatment developments and positive technical signals, investors have both fundamental and technical reasons to closely monitor Johnson & Johnson.

Read Next:

Photo: Shutterstock